Form 51-102F3

Material Change Report

Item 1 – Name and Address of Company

Kovo HealthTech Corporation

1600 – 925 West Georgia Street

Vancouver, BC

V6C 3L2

Item 2 - Date of Material Change

November 3, 2021

Item 3 - News Release

News release pre-reviewed by IIROC and issued via newswire to the business disclosure network. [see attached]

Item 4 - Summary of Material Change

Kovo HealthTech Corporation announced it had closed a brokered private placement. The TSXV approved the placement on November 3, 2021.

Item 5 - Full Description of Material Change Full Description of Material Change

Kovo HealthTech Corporation (TSXV: KOVO) (the "**Company**" **"Kovo"**) — a leader in healthcare technology and Billing-as-a-Service — announced it closed its previously announced brokered private placement (the "**Private Placement**") offering.

The Company expects to use net proceeds for working capital requirements and to fund potential future acquisitions.

As part of the Private Placement, which was led by Research Capital Corporation ("the **Agent**") as sole agent and sole bookrunner, the Company issued 3,012,500 Units at a price of $0.40 per Unit (the "**Offering Price**") for aggregate gross proceeds of $1,205,000.

Each Unit consists of one common share (each, a "**Common Share**", and collectively the "**Common Shares**") and one common share purchase warrant (a "**Warrant**" and collectively the "**Warrants**"). Each Warrant entitles the holder thereof to acquire one Common Share at a price of C$0.70 per Common Share for a period of 24 months from the closing date of the Offering, subject to acceleration as described below. The Warrants will be subject to early expiration if, at any time prior to the expiry date of the Warrants, the volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the "**TSXV**"), or other principal exchange on which the Common Shares are listed, is greater than C$1.00 for 10 consecutive trading days.

Pursuant to applicable Canadian securities laws, the securities issued and issuable in connection with the Offering will be subject to a hold period of 4 months ending on February 25, 2022. The Private Placement remains subject to final approval from the TSXV.

In connection with the Private Placement, the Agent received an aggregate cash fee equal to $53,625 and an aggregate of 134,063 non-transferable broker warrants (the "**Broker Warrants**"). Each Broker Warrant entitles the holder thereof to purchase one Unit at an exercise price equal to the Offering Price for a period of 24 months following the closing of the Private Placement.

5.2 - Disclosure for Restructuring Transactions

NA

Item 6 - Reliance on subsection 7.1(2) of National Instrument 51-102

NA

Item 7 - Omitted Information

NA

Item 8 Executive Officer

Greg Noble

CEO, Kovo HealthTech Corporation

1-866-558-6777

Item 9 - Date of Report

November 10, 2021.

[Amended July 4, 2008]